|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001563,
umls-concept:C0017066,
umls-concept:C0029216,
umls-concept:C0033262,
umls-concept:C0201734,
umls-concept:C0376387,
umls-concept:C0440790,
umls-concept:C0524930,
umls-concept:C0909381,
umls-concept:C1979963,
umls-concept:C2003903
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2005-5-5
|
|
pubmed:abstractText |
Valganciclovir (Valcyte) has recently been approved for the prevention of cytomegalovirus (CMV) disease in high-risk (CMV donor positive [D+]/recipient negative [R-]) solid organ transplant (SOT) recipients. Large-scale studies describing the pharmacokinetics of valganciclovir in SOT recipients are lacking. A recent randomised, double-blind study of valganciclovir in 364 D+/R- (intent-to-treat population) SOT recipients provided valuable data on which a population pharmacokinetic analysis was performed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0312-5963
|
|
pubmed:author |
pubmed-author:AlexanderBarbaraB,
pubmed-author:BlumbergEmilyE,
pubmed-author:DominguezEdwardE,
pubmed-author:FarrellColmC,
pubmed-author:FreemanRichardR,
pubmed-author:HeatonNigelN,
pubmed-author:HirankarnSarapeeS,
pubmed-author:HumarAtulA,
pubmed-author:PayaCarlosC,
pubmed-author:PescovitzMark DMD,
pubmed-author:Valganciclovir Solid Organ Transplant Study Group,
pubmed-author:WashburnKennethK,
pubmed-author:WiltshireHughH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
495-507
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15871635-Administration, Oral,
pubmed-meshheading:15871635-Adult,
pubmed-meshheading:15871635-Aged,
pubmed-meshheading:15871635-Antiviral Agents,
pubmed-meshheading:15871635-Area Under Curve,
pubmed-meshheading:15871635-Cytomegalovirus Infections,
pubmed-meshheading:15871635-Female,
pubmed-meshheading:15871635-Ganciclovir,
pubmed-meshheading:15871635-Humans,
pubmed-meshheading:15871635-Male,
pubmed-meshheading:15871635-Middle Aged,
pubmed-meshheading:15871635-Models, Biological,
pubmed-meshheading:15871635-Organ Transplantation,
pubmed-meshheading:15871635-Prodrugs
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
|
|
pubmed:affiliation |
Roche Products Ltd, Welwyn Garden City, UK.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
